VERTEX PHARMACEUTICALS INC / MA Available-for-sale Securities, Amortized Cost Basis
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Available-for-sale Securities, Amortized Cost Basis of $1.34 billion as of 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-02-13
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $1.34B.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $392.23M; Available-for-sale Securities, Amortized Cost Basis as first filed $1.08B.
- 2012-09-30: Available-for-sale Securities, Amortized Cost Basis $1.30B.
- 2012-06-30: Available-for-sale Securities, Amortized Cost Basis $1.22B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-03-31 | $1.34B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $392.23M 10-K · filed 2019-02-13 | $1.08B 10-Q · filed 2018-04-27 |
| 2012-09-30 | $1.30B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $1.22B 10-Q · filed 2012-08-08 | |
| 2011-12-31 | $969.03M 10-Q · filed 2012-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |